Bone fractures associated with luteinizing hormone - Releasing hormone agonists used in the treatment of prostate carcinoma

Cancer

Volumn 79, Issue 3, 1997, Pages 545-550

  Townsend, Murphy F ^a   Holt Sanders, W ^a,b   Northway, Robert O ^a   Graham Jr , Sam D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

Author keywords

hormonal therapy; osteoporosis; prostate carcinoma

Indexed keywords

GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ARTICLE; BONE INJURY; FRACTURE; HUMAN; INTERVIEW; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TRAFFIC ACCIDENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FRACTURES, SPONTANEOUS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; MEDICAL RECORDS; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 1842288643     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3     Document Type: Article

References (44)

1. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahan DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A 1989;86:854-7.
2. Kasperk CH, Wegedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989;124:1576-8.
3. Orwoll ES, Stribrska L, Ramsey EE, Keenan EJ. Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int 1991;49:182-7.
4. Carrascosa A, Audi L, Ferrandez MA, Ballabriga A. Biological effects of androgens and identification of specific dihydrotestosterone-binding sites in cultured human fetal epiphyseal chondrocytes. J Clin Endocrinol Metab 1990;70:134-40.
5. Kapur SP, Reddi AH. Influence of testosterone and dihydrotestosterone on bone-matrix induced endochondral bone formation. Calcif Tissue Int 1989;44:108-13.
6. Kasperk C, Fitzisimmons R, Strong D, Mohan S, Jennings J, Wergedal J, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 1990;71:1322-9.
7. Corvol MT, Carrascosa A, Tsagris L, Blanchard O, Rappaport R. Evidence for a direct in vitro action of sex steroids on rabbit cartilage cells during skeletal growth: influence of age and sex. Endocrinology 1987;120:1422-9.
8. Garn SM, Sullivan TV, Decker SA, Larkin FA, Hawthorne VM. Continuing bone expansion and increasing bone loss over a two-decade period in men and women from a total community sample. Am J Hum Biol 1992;4:57-67.
9. Melsen F, Melsen B, Mosekilde L, Bergmann S. Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand 1986;86:70-81.
10. Bardin CW, Swerdloff RS, Santen RJ. Androgens: risk and benefits [special article]. J Endocrinol Metab 1991;73:4-17.
11. Murphy S, Khaw KT, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner 1992;20:133-40.
12. Kelly PJ, Pocock NA, Sambrook PN, Eisman JA. Dietary calcium, sex hormones, and bone mineral density in men. Br Med J 1990;300:1361-4.
13. Finkelstein JS, Klibanski A, Neer RM, Greenspan SI, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106:354-61.
14. Smith DAS, Walker M. Changes in plasma steroids and bone density in Kleinfelter's syndrome. Calcif Tissue Int 1977; 22(Suppl):225-8.
15. Arisaka O, Arisaka M. Effect of testosterone on radial bone mineral density in adolescent male hypogonadism. Acta Paediatr Scand 1991;80:378-80.
16. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-7.
17. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986;104:777-82.
18. Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989;110:526-31.
19. Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991;6:39-43.
20. Fogelman I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992;57:715-24.
21. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87-116.
22. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990;263:2335-40.
23. Niewoehner C. Osteroporosis in men: is it more common than we think? Postgrad Med 1993;93:59-70.
24. Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. Am J Med 1993;95:22S-28S.
25. Sandow J, Fraser HM, Geisthovel F. Pharmacology and experimental basis of therapy with LHRH agonists in women. Prog Clin Biol Res 1986;225:1-27.
26. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76:288-90.
27. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 1987;8:279-84.
28. Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab 1991;73:221-4.
29. Vermeulen A, Kaufman JM. Role of the hypothalamo-pituitary function in the hypoandrogenism of healthy aging [editorial]. J Clin Endocrinol Metab 1992;75:704-6.
30. Francis RM, Peacock M. Marshall DH, Horsman A, Aaron JE. Spinal osteoporosis in men. Bone Miner 1989;5:347-57.
31. Seeman E, Melton LJ III. Risk factors for spinal osteoporosis in men. Am J Med 1983;75:977-83.
32. Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine 1990;69:137-52.
33. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991;39:766-71.
34. Mann T, Oviatt SK, Wilson D, Nelson D, Orwoll ES. Vertebral deformity in men. J Bone Miner Res 1992;7:1259-65.
35. Chevalley T, Rizzoli R, Nydegger V, Slosman D, Tkatch L, Rapin C-H, et al. Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur. Osteoporos Int 1991;1:147-54.
36. Karlsson MK, Johnell O, Nilsson BE, Sernbo I, Obrant KJ. Bone mineral mass in hip fracture patients. Bone 1993;14:161-5.
37. Melton LJ III, Rigg BL. Epidemiology of age-related fractures. In: Avioli LV. The Osteoporotic Syndrome. Volume 45. New York: Grune & Stratton, 1983:45-72.
38. Horan AH. Fractures ascribable to osteoporosis following LHRH antagonism for carcinoma of the prostate: a preliminary survey. Presented at the 70th annual meeting of the Western Section-AUA in Seattle, August 1994.
39. Collinson MP, Tyrrell CJ, Hutton C. Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 1994;54:327-8.
40. Maillefert JF, Sibilia J, Kuntz JL, Tavernier C. Gonadotrophin-releasing hormone agonists induce osteoporosis. Br J Rheumatol 1994;33:1199-1200.
41. Tourliere D, Viala JF, Benhamou CL. Osteoporose aux analogues de la LHRH chez un homme traite pour cancer de la prostate [abstract B14]. Rev Rhum 1992;59:624.
42. Prier A, Arnoult C, de Vernejoul MC, Kaplan C. Analogues de la LHRH: une cause d'osteoporose vertebrale chez l'homme? [abstract G24] Rev Rhum 1993;60:715.
43. Bacon WE, Smith GS, Baker SP. Geographic variation in the occurrence of hip fractures among the elderly white population. Am J Public Health 1989;79:1556-8.
44. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health 1990;80:871-3.